GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » EV-to-FCF

Anavex Life Sciences (STU:12X1) EV-to-FCF : -15.73 (As of Apr. 06, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anavex Life Sciences's Enterprise Value is €520.74 Mil. Anavex Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-33.11 Mil. Therefore, Anavex Life Sciences's EV-to-FCF for today is -15.73.

The historical rank and industry rank for Anavex Life Sciences's EV-to-FCF or its related term are showing as below:

STU:12X1' s EV-to-FCF Range Over the Past 10 Years
Min: -16.15   Med: 0   Max: 0
Current: -16.15

STU:12X1's EV-to-FCF is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 2.335 vs STU:12X1: -16.15

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-06), Anavex Life Sciences's stock price is €7.424. Anavex Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.510. Therefore, Anavex Life Sciences's PE Ratio (TTM) for today is At Loss.


Anavex Life Sciences EV-to-FCF Historical Data

The historical data trend for Anavex Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences EV-to-FCF Chart

Anavex Life Sciences Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.89 -39.84 -27.03 -13.91 -11.34

Anavex Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.17 -8.81 -7.30 -11.34 -22.24

Competitive Comparison of Anavex Life Sciences's EV-to-FCF

For the Biotechnology subindustry, Anavex Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's EV-to-FCF falls into.


;
;

Anavex Life Sciences EV-to-FCF Calculation

Anavex Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=520.737/-33.11
=-15.73

Anavex Life Sciences's current Enterprise Value is €520.74 Mil.
Anavex Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anavex Life Sciences  (STU:12X1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Anavex Life Sciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.424/-0.510
=At Loss

Anavex Life Sciences's share price for today is €7.424.
Anavex Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.510.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Anavex Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Headlines

No Headlines